Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads
1. 请及时下载文件确认是否正确, 系统将在 2026-03-14 13:38:37 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1021/acs.jmedchem.1c01595
文献链接: https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01595
其他信息:
出版社: American Chemical Society (ACS)
作者: Mingzong Li; Zenon Konteatis; Nelamangala Nagaraja; Yue Chen; Shubao Zhou; Guangning Ma; Stefan Gross; Katya Marjon; Marc L. Hyer; Everton Mandley; Max Lein; Anil K. Padyana; Lei Jin; Shuilong Tong; Rachel Peters; Joshua Murtie; Jeremy Travins; Matthew Medeiros; Peng Liu; Victoria Frank; Evan T. Judd; Scott A. Biller; Kevin M. Marks; Zhihua Sui; Samuel K. Reznik

